

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

SKOV3.ip1

RRID:CVCL_0C84

Type: Cell Line

Proper Citation

RRID:CVCL_0C84

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0C84

Proper Citation: RRID:CVCL_0C84

Description: Cell line SKOV3.ip1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous cystadenocarcinoma

Defining Citation: [PMID:8094034](#), [PMID:23552738](#), [PMID:27561551](#), [PMID:28196595](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SKOV3.ip1

Synonyms: SKOV3-ip1, Skov3-ip1, SKOV3ip1, SKOV3IP1, SKOV3IP

Cross References: BTO:BTO_0006557, cancercelllines:CVCL_0C84, PRIDE:PXD003668, Wikidata:Q54954770

ID: CVCL_0C84

Hierarchy: cvcl_0532

Record Creation Time: 20220427T221548+0000

Record Last Update: 20260829T235938+0000

Ratings and Alerts

No rating or validation information has been found for SKOV3.ip1.

No alerts have been found for SKOV3.ip1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sanchez-Pupo RE, et al. (2026) Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters. *Theranostics*, 16(7), 3227.

Surmann H, et al. (2026) Prognostic influence of small leucine-rich proteoglycans on serous ovarian cancer. *Journal of cancer research and clinical oncology*, 152(6).

Elhaw AT, et al. (2026) RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. *Cancer research*, 86(11), 2623.

Meng Y, et al. (2026) IPO9 Promotes Ovarian Cancer Progression by Suppressing HMOX1-Dependent Ferroptosis. *Human mutation*, 2026, 8545131.

Wen F, et al. (2025) LPCAT3 regulates the proliferation and metastasis of serous ovarian cancer by modulating arachidonic acid. *Translational oncology*, 52, 102256.

Jeevarathinam AS, et al. (2025) Directional conjugation of monoclonal antibodies to nanoparticles using metal-free click chemistry. *Nature protocols*.

Sencha LM, et al. (2025) Cell-type dependent effect of 3D collagen matrix on cancer cell resistance to suboptimal conditions: the case of serum deprivation, glucose starvation, and hypoxia. *Tissue & cell*, 93, 102719.

Bayraktar E, et al. (2025) Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. *Cell reports. Medicine*, 6(9), 102329.

Meng Y, et al. (2024) METTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via regulation of the mTOR/AKT pathway and its link to the tumor immune microenvironment. *BMC cancer*, 24(1), 1455.

Lee YY, et al. (2024) The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression. *Cancer cell international*, 24(1), 43.

Glassman D, et al. (2023) Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. *iScience*, 26(2), 106020.

Faucher-Giguère L, et al. (2022) High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival. *NAR cancer*, 4(1), zcab050.

Cumin C, et al. (2022) Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. *Cell reports*, 40(7), 111181.

Handley KF, et al. (2021) Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. *Molecular cancer therapeutics*, 20(12), 2352.

Huang YL, et al. (2021) Site-specific N-glycosylation of integrin $\alpha 2$ mediates collagen-dependent cell survival. *iScience*, 24(10), 103168.

Curtis M, et al. (2019) Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. *Cell metabolism*, 29(1), 141.